Roxatidine acetate | CAS# 78628-28-1 | Anti-ulcer agent

MedKoo Cat#: 571506 | Name: Roxatidine acetate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Roxatidine acetate is an anti-ulcer agent and histamine antagonist that suppresses gastric acid secretion. It effectively heals duodenal and gastric ulcers and reduces ulcer pain. Roxatidine acetate has an improved safety profile compared to other similar drugs, in part because lower doses of roxatidine acetate are therapeutically effective.

Chemical Structure

Roxatidine acetate

CAS#78628-28-1 (roxatidine acetate)

Theoretical Analysis

MedKoo Cat#: 571506

Name: Roxatidine acetate

CAS#: 78628-28-1 (roxatidine acetate)

Chemical Formula: C19H28N2O4

Exact Mass: 348.2049

Molecular Weight: 348.44

Elemental Analysis: C, 65.49; H, 8.10; N, 8.04; O, 18.37

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

78273-80-0 (free base) 93793-83-0 (Acetate Hydrochloride) 78628-28-1 (roxatidine acetate)

Synonym

Roxatidine acetate

IUPAC/Chemical Name

Acetamide, 2-(acetyloxy)-N-(3-(3-(1-piperidinylmethyl)phenoxy)propyl)-

InChi Key

SMTZFNFIKUPEJC-UHFFFAOYSA-N

InChi Code

InChI=1S/C19H28N2O4/c1-16(22)25-15-19(23)20-9-6-12-24-18-8-5-7-17(13-18)14-21-10-3-2-4-11-21/h5,7-8,13H,2-4,6,9-12,14-15H2,1H3,(H,20,23)

SMILES Code

O=C(NCCCOC1=CC=CC(CN2CCCCC2)=C1)COC(C)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 348.44 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Nakamura H, Kawashima H, Azuma R, Sato I, Nagao K, Miyazawa K. Pharmacokinetics of the H(2) blocker roxatidine acetate hydrochloride in pediatric patients, in comparison with healthy adult volunteers. Drug Metab Pharmacokinet. 2012;27(4):422-9. Epub 2012 Jan 31. PubMed PMID: 22293541. 2: Maheshwari A, Sharma M, Sharma D. Investigation of the binding of roxatidine acetate hydrochloride with cyclomaltoheptaose (β-cyclodextrin) using IR and NMR spectroscopy. Carbohydr Res. 2011 Sep 27;346(13):1809-13. doi: 10.1016/j.carres.2011.07.003. Epub 2011 Jul 18. PubMed PMID: 21816394. 3: Dammann HG, de Looze SM, Bender W, Labs R. Clinical characteristics of roxatidine acetate: a review. Scand J Gastroenterol Suppl. 1988;146:121-34. Review. PubMed PMID: 2906456. 4: Merki HS, Bender W, Labs R. Safety and efficacy of roxatidine acetate. Evidence from pharmacodynamic and clinical trials. J Clin Gastroenterol. 1989;11 Suppl 1:S20-3; discussion S24. PubMed PMID: 2572621. 5: Bickel M, Herling AW, Schoelkens B, Scholtholt J. Chemical and biologic characteristics of roxatidine acetate. Scand J Gastroenterol Suppl. 1988;146:78-88. PubMed PMID: 2906471. 6: Scholtholt J, Bickel M, Herling AW. A review of the animal pharmacology of roxatidine acetate. Drugs. 1988;35 Suppl 3:30-40. Review. PubMed PMID: 2905247. 7: Nakamura K, Akiho H, Ochiai T, Motomura Y, Higuchi N, Okamoto R, Matsui N, Yasuda D, Akahoshi K, Kabemura T, Ihara E, Harada N, Ito T, Takayanagi R. Randomized controlled trial: roxatidine vs omeprazole for non-erosive reflux disease. Hepatogastroenterology. 2010 May-Jun;57(99-100):497-500. PubMed PMID: 20698216. 8: Hagenmüller F. Effect of roxatidine acetate on daytime and night-time peptone-stimulated gastric acid secretion. Drugs. 1988;35 Suppl 3:65-8. PubMed PMID: 2905251. 9: Cho EJ, An HJ, Shin JS, Choi HE, Ko J, Cho YW, Kim HM, Choi JH, Lee KT. Roxatidine suppresses inflammatory responses via inhibition of NF-κB and p38 MAPK activation in LPS-induced RAW 264.7 macrophages. J Cell Biochem. 2011 Dec;112(12):3648-59. doi: 10.1002/jcb.23294. PubMed PMID: 21809375. 10: Iida H, Kato S, Sekino Y, Sakai E, Uchiyama T, Endo H, Hosono K, Sakamoto Y, Fujita K, Yoneda M, Koide T, Takahashi H, Tokoro C, Goto A, Abe Y, Kobayashi N, Kubota K, Gotoh E, Maeda S, Nakajima A, Inamori M. Early effects of oral administration of omeprazole and roxatidine on intragastric pH. J Zhejiang Univ Sci B. 2012 Jan;13(1):29-34. doi: 10.1631/jzus.B1100078. PubMed PMID: 22205617; PubMed Central PMCID: PMC3251749. 11: Merki HS, Witzel L, Kaufmann D, Kempf M, Müssig V, Neumann J, Scheurle E, Röhmel J, Walt RP. The effects of roxatidine acetate (HOE-760) on 24-hour intragastric acidity in healthy volunteers: comparison with ranitidine and placebo. Aliment Pharmacol Ther. 1988 Feb;2(1):73-81. PubMed PMID: 2908751. 12: Murdoch D, McTavish D. Roxatidine acetate. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic potential in peptic ulcer disease and related disorders. Drugs. 1991 Aug;42(2):240-60. Review. PubMed PMID: 1717223. 13: Tsutsumi M, Ueshima Y, Takase S. Pharmacokinetics of roxatidine acetate in patients with chronic liver disease. J Gastroenterol Hepatol. 2001 Aug;16(8):910-5. PubMed PMID: 11555106. 14: Agrawal SS, Alvin Jose M. Roxatidine, an H(2) receptor blocker, is an estrogenic compound--experimental evidence. Syst Biol Reprod Med. 2010 Aug;56(4):286-91. doi: 10.3109/19396368.2010.496894. PubMed PMID: 20718616. 15: Hüttemann W. A comparison of roxatidine acetate and ranitidine in duodenal ulcer healing. Drugs. 1988;35 Suppl 3:90-5. PubMed PMID: 2905255. 16: Roxatidine acetate as maintenance treatment for patients with peptic ulcer disease. The European Cooperative Roxatidine Study Group. Clin Ther. 1991 Jan-Feb;13(1):47-57. PubMed PMID: 1674231. 17: Namba M, Chihara E, Ibuki T, Ashida H, Fukushima H, Tanaka Y. [Clinical evaluation of roxatidine acetate hydrochlorides as a preanesthetic medication]. Masui. 2001 Feb;50(2):127-35. Japanese. PubMed PMID: 11244765. 18: Hemery P, Congard P, Galmiche JP, Bonfils S. Effects of roxatidine acetate on 24-hour gastric acidity. Early evening versus bedtime administration in healthy subjects. Drugs. 1988;35 Suppl 3:76-81. PubMed PMID: 2905253. 19: Lassman HB, Ho I, Puri SK, Sabo R, Scheffler MR. The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men. Drugs. 1988;35 Suppl 3:53-64. PubMed PMID: 2905250. 20: Shiratsuchi K, Fuse H, Hagiwara M, Mikami T, Miyasaka K, Sakuma H. Cytoprotective action of roxatidine acetate HCl. Arch Int Pharmacodyn Ther. 1988 Jul-Aug;294:295-304. PubMed PMID: 2906796.